<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757391</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0152</org_study_id>
    <secondary_id>NCI-2016-01058</secondary_id>
    <secondary_id>2015-0152</secondary_id>
    <nct_id>NCT02757391</nct_id>
  </id_info>
  <brief_title>CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors</brief_title>
  <official_title>Pilot Study of Feasibility and Safety of Personalized Autologous CD8+ T Cell Therapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T&#xD;
      cells in treating patients with gastrointestinal tumors that have spread to other places in&#xD;
      the body. Tumor cells and blood are used to help create an adoptive T cell therapy, such as&#xD;
      CD8+ T cell therapy, that is individually designed for a patient and may help doctors learn&#xD;
      more about genetic changes in the tumor. Immunotherapy with monoclonal antibodies, such as&#xD;
      pembrolizumab, may help the body's immune system attack the cancer, and may interfere with&#xD;
      the ability of tumor cells to grow and spread. Giving CD8+ T cell therapy and pembrolizumab&#xD;
      may work better in treating patients with gastrointestinal tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the safety of using a personalized adoptive T cell therapy in patients with&#xD;
      advanced gastrointestinal malignancies.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the persistence of an immune response after T cell infusion. II. Determine the&#xD;
      clinical benefit of adoptive T cell therapy in advanced gastrointestinal cancers.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Beginning 2 days prior to CD8+ T cell infusion, patients receive cyclophosphamide&#xD;
      intravenously (IV) over 30 minutes. Patients undergo CD8+ T cell infusion IV over 2 hours on&#xD;
      day 0 and receive aldesleukin subcutaneously (SC) twice daily (BID) on days 1-14. Beginning&#xD;
      on day 1 about 24 hours after CD8+ T cell infusion, patients receive pembrolizumab IV over&#xD;
      30-60 minutes on weeks 3, 6, 12, and 15.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study halted prematurely and will not resume; participants are no longer being examined or&#xD;
    receiving intervention.&#xD;
  </why_stopped>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Actual">October 2, 2020</completion_date>
  <primary_completion_date type="Actual">October 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxicity defined as grade 3 or 4 non-hematologic or grade 4 hematologic toxicity per Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Will monitor toxicity of the personalized vaccines in using cohorts of size of 5, starting from the 1st patient using the Bayesian approach of Thall, Simon, Estey.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of an immune response defined by level of tetramer positive T cell population over time after T cell infusion</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of an immune response defined by T cell interferon gamma release in response to selected personalized peptide antigens</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of an immune response defined by levels of intracellular cytokine staining of T cells in response to stimulation with personalized peptide antigens</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of an immune response defined by detection of antigen spreading</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have received T cell infusion that is alive and progression free (complete response [CR] + partial response [PR] + stable disease) defined based on response criteria according to Response Evaluation Criteria in Solid Tumors 1.1</measure>
    <time_frame>At 12 weeks post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR + PR)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The response rate will be evaluated using a Simon optimal two-stage design.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Colorectal Adenocarcinoma</condition>
  <condition>Metastatic Cholangiocarcinoma</condition>
  <condition>Metastatic Colorectal Carcinoma</condition>
  <condition>Metastatic Digestive System Carcinoma</condition>
  <condition>Metastatic Esophageal Carcinoma</condition>
  <condition>Metastatic Gastric Carcinoma</condition>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <condition>Stage IV Colorectal Cancer AJCC v7</condition>
  <condition>Stage IV Esophageal Cancer AJCC v7</condition>
  <condition>Stage IV Gastric Cancer AJCC v7</condition>
  <condition>Stage IV Pancreatic Cancer AJCC v6 and v7</condition>
  <condition>Stage IVA Colorectal Cancer AJCC v7</condition>
  <condition>Stage IVB Colorectal Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (CD8 +T cell therapy, pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 2 days prior to CD8+ T cell infusion, patients receive cyclophosphamide IV over 30 minutes. Patients undergo CD8+ T cell infusion IV over 2 hours on day 0 and receive aldesleukin SC BID on days 1-14. Beginning on day 1 about 24 hours after CD8+ T cell infusion, patients receive pembrolizumab IV over 30-60 minutes on weeks 3, 6, 12, and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adoptive Immunotherapy</intervention_name>
    <description>Undergo CD8 +T cell therapy</description>
    <arm_group_label>Treatment (CD8 +T cell therapy, pembrolizumab)</arm_group_label>
    <other_name>ACT</other_name>
    <other_name>ACT Therapy</other_name>
    <other_name>Adoptive Cell Immunotherapy</other_name>
    <other_name>Adoptive Cell Transfer</other_name>
    <other_name>Adoptive Cell Transfer Immunotherapy</other_name>
    <other_name>Adoptive Cell Transfer Therapy</other_name>
    <other_name>adoptive cellular immunotherapy</other_name>
    <other_name>adoptive cellular therapy</other_name>
    <other_name>cellular adoptive immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (CD8 +T cell therapy, pembrolizumab)</arm_group_label>
    <other_name>125-L-Serine-2-133-interleukin 2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>r-serHuIL-2</other_name>
    <other_name>Recombinant Human IL-2</other_name>
    <other_name>Recombinant Human Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CD8 +T cell therapy, pembrolizumab)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (CD8 +T cell therapy, pembrolizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CD8 +T cell therapy, pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. Histopathologic documentation of pancreatic adenocarcinoma, colorectal adenocarcinoma,&#xD;
             cholangiocarcinoma, esophageal cancer and gastric cancer with radiographic evidence of&#xD;
             metastatic disease.&#xD;
&#xD;
          2. Male or female subjects greater than or equal to 18 years of age.&#xD;
&#xD;
          3. ECOG/ Zubrod performance status of 0 or 1.&#xD;
&#xD;
          4. Women of childbearing potential (WOCBP) must be using an adequate method of&#xD;
             contraception to avoid pregnancy throughout the study in such a manner that the risk&#xD;
             of pregnancy is minimized. Suggested precautions should be used to minimize the risk&#xD;
             or pregnancy for at least 1 month before start of therapy, and while women are on&#xD;
             study for at least 8 weeks after pembrolizumab is stopped. WOCBP include any female&#xD;
             who has experienced menarche and who has not undergone successful surgical&#xD;
             sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is&#xD;
             not postmenopausal. Acceptable forms of birth control include condom, diaphragm,&#xD;
             hormonal, IUD, or sponge plus spermacide. Abstinence is also an acceptable form of&#xD;
             birth control.&#xD;
&#xD;
          5. Men must be willing and able to use an acceptable method of birth control, during and&#xD;
             for at least 3 months after completion of the study, if their sexual partners are&#xD;
             WOCBP.&#xD;
&#xD;
          6. Willing and able to give informed consent.&#xD;
&#xD;
          7. Adequate vein access: consider PICC or other central line.&#xD;
&#xD;
          8. Patients must have adequate tissue (fresh or frozen) available or planned removal of&#xD;
             adequate tissue for analysis. At least 250mg of tumor are needed for peptide elution.&#xD;
             There is no specific time limit on how long the tissue can remain frozen prior to use.&#xD;
             The tissue will be collected and analyzed under Lab protocol PA15-0176.&#xD;
&#xD;
          9. Patients can have any lines (including zero) of prior therapy to sign consent prior to&#xD;
             tissue harvest.&#xD;
&#xD;
         10. Toxicity related to prior therapy must either have returned to &lt;/= grade 1, baseline,&#xD;
             or been deemed irreversible.&#xD;
&#xD;
         11. ELIGIBILITY FOR TREATMENT: ECOG/Zubrod performance status of 0 to 2.&#xD;
&#xD;
         12. Bi-dimensionally measurable disease by radiographic imaging (CT scan) that represents&#xD;
             at least one measurable lesion per RECIST v1.1.&#xD;
&#xD;
         13. At least 4 Weeks must have elapsed since the last chemotherapy, radiotherapy or major&#xD;
             surgery.&#xD;
&#xD;
         14. Toxicity related to prior therapy must either have returned to less than or equal to&#xD;
             grade 1, baseline, or been deemed irreversible.&#xD;
&#xD;
         15. Subjects must have received at least one line of chemotherapy prior to receiving&#xD;
             adoptive T cell therapy and should have exhausted standard of care systemic therapy&#xD;
             options. The decision to implement the T cell therapy will be at the discretion of the&#xD;
             treating physician. The timing and total exposure to chemotherapy will depend on the&#xD;
             tumor type in question (more systemic options for breast cancer; fewer for gastric&#xD;
             cancer, for example). Due to the heterogeneity of tumors being treated in this&#xD;
             protocol, the discretion of the treating physician in terms of timing of immunotherapy&#xD;
             will be critical.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. EXCLUSION FOR ENROLLMENT: Any other malignancy from which the patient has been&#xD;
             disease-free for less than 5 years, with the exception of adequately treated and cured&#xD;
             basal or squamous cell skin cancer, superficial bladder cancer, and carcinoma in situ&#xD;
             of the cervix.&#xD;
&#xD;
          2. Pregnant women, nursing mothers, men or women of reproductive ability who are&#xD;
             unwilling to use effective contraception. Women of childbearing potential with a&#xD;
             positive pregnancy test within 3 days prior to entry.&#xD;
&#xD;
          3. Significant cardiovascular abnormalities as defined by any one of the following: 1.&#xD;
             Congestive heart failure NYHA classes II-IV. Patients with asymptomatic class I CHF&#xD;
             may participate in conjunction with a Cardiology consultation. 2. Clinically&#xD;
             significant hypotension. 3. Symptoms of coronary artery disease. 4. Presence of&#xD;
             arrhythmias in EKG requiring drug therapy.&#xD;
&#xD;
          4. Active and untreated central nervous system (CNS) metastases (including metastasis&#xD;
             identified during screening MRI or contrast CT). Patients with asymptomatic, treated&#xD;
             metastases may be eligible if their lesion(s) have demonstrated stability over 2&#xD;
             months.&#xD;
&#xD;
          5. Autoimmune disease: Patients with a history of Inflammatory Bowel Disease are excluded&#xD;
             from this study, as are patients with a history of autoimmune disease (e.g. Systemic&#xD;
             Lupus Erythematosus, vasculitis, infiltrating lung disease) whose possible progression&#xD;
             during treatment would be considered by the Investigator to be unacceptable.&#xD;
&#xD;
          6. Any underlying medical or psychiatric condition, which in the opinion of the&#xD;
             Investigator, will make the administration of study drug hazardous or obscure the&#xD;
             interpretation of adverse events, such as a condition associated with frequent&#xD;
             diarrhea.&#xD;
&#xD;
          7. Inadequate organ function at enrollment defined by: WBC less than or equal to 2000/uL.&#xD;
             Hct less than or equal to 24% or Hgb less than or equal to 8 g/dL. ANC less than or&#xD;
             equal to 1000. Platelets less than or equal to 75,000. Creatinine greater than or&#xD;
             equal to 1.5 x ULN OR creatinine clearance &gt;50 ml/min/1.73m2 for patients with&#xD;
             creatinine levels above institutional normal limits. AST/ALT greater than or equal to&#xD;
             2.5 x ULN. Bilirubin greater than or equal to 2.0 x ULN&#xD;
&#xD;
          8. Positive screening tests for HIV, Hep B, and Hep C. If positive results are not&#xD;
             indicative of true active or chronic infection, the patient can be treated&#xD;
&#xD;
          9. EXCLUSION CRITERIA FOR TREATMENT: WBC less than or equal to 2000/uL. Hct less than or&#xD;
             equal to 24% or Hgb less than or equal to 8 g/dL. ANC less than or equal to 1000.&#xD;
             Platelets less than or equal to 75,000. Creatinine greater than or equal to 1.5 x ULN&#xD;
             OR creatinine clearance &gt;50 ml/min/1.73m2 for patients with creatinine levels above&#xD;
             institutional normal limits. AST/ALT greater than or equal to 2.5 x ULN. Bilirubin&#xD;
             greater than or equal to 2.0 x ULN&#xD;
&#xD;
         10. Pregnant women, nursing mothers, men or women of reproductive ability who are&#xD;
             unwilling to use effective contraception. Women of childbearing potential with a&#xD;
             positive pregnancy test within 3 days prior to entry.&#xD;
&#xD;
         11. Steroids are not permitted 3 days prior to T cell infusion and concurrently during&#xD;
             therapy.&#xD;
&#xD;
         12. Uncontrolled concurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
         13. Any non-oncology vaccine therapy used for the prevention of infectious disease within&#xD;
             1 month before or after any anti-PD-1 dose.&#xD;
&#xD;
         14. After the T cell infusion, patients may not be on any other treatments for their&#xD;
             cancer aside from those included in the treatment section of the protocol.&#xD;
&#xD;
         15. Coagulation â‰¤1.5 x ULN unless participant is receiving anticoagulant therapy as long&#xD;
             as PT or a PTT is within therapeutic range of intended use of anticoagulants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Overman</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

